Pakistan Bait-ul-Maal has announced the toll out of key initiatives including NAI-ZINDGI drug rehabilitation center, Pakistan Cancer ...

Owing to Briumvi's solid launch, TG's balance sheet is in excellent condition. Despite new competition, Briumvi's five-year ...

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F. Kennedy Jr. reportedly plans to dissolve the U.S. Preventive Services Task ...

Whether you’re dealing with breakouts, uneven skin tone, or even signs of aging, azelaic acid might just be the missing ...

The company is bullish about its prospects in the second half of the year, despite ongoing economic and geopolitical ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The EU 15% tariff will raise prices on European consumer brands from luxury, autos, food and beauty. This could reduce demand ...

Locally based development and investment firm Prism Capital Partners has received three redevelopment plan approvals from the City of Clifton and the Township of Nutley, both located in Northern New ...

The MTA’s plan to modernize signals on the G train will take longer than planned, transit officials said Monday, with an ...

The Williamsport Crosscutters left all the dramatics on the field Tuesday night, earning a series-opening win over the ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...